Sunitinib plus paclitaxel in patients with advanced esophageal cancer: A phase II study from the Hoosier Oncology Groupe

Jordan M. Schmitt, Scott R. Sommers, William Fisher, Rafat Ansari, Erwin Robin, Karuna Koneru, John McClean, Ziyue Liu, Yan Tong, Nasser Hanna

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

The combination of sunitinb (37.5 mg orally daily) + paclitaxel (90 mg/m intravenously on days 1, 8, 15 every 4 weeks) was examined in patients with advanced esophageal or gastroesophageal junction cancer, and progression-free survival (PFS) was compared to that of historical controls. The end points included response rate, overall survival, and toxicities. Twenty-eight patients were enrolled at six centers. Median age was 59.5 years. The 24-week PFS rate was 25% (90% confidence interval [CI], 12-42%). Three (11%) of 23 evaluable patients had a response (1 complete response and 2 partial response) (90% CI, 3-25%). Median overall survival was 228 days (90% CI, 140-283 days). Grade 3/4 toxicities included leukopenia/neutropenia (25%), anemia (18%), fatigue (11%), and hemorrhage (11%). There were four grade 5 toxicities including upper gastrointestinal hemorrhage (n = 2), gastrointestinal/esophageal fistula (n = 1), and unexplained death (n = 1). In our study, we found that sunitinib + paclitaxel in patients with advanced esophageal or gastroesophageal junction cancer had a 24-week PFS no better than the PFS of historical controls. The combination also had a high rate of serious toxicities and will not be pursued.

Original languageEnglish (US)
Pages (from-to)760-763
Number of pages4
JournalJournal of Thoracic Oncology
Volume7
Issue number4
DOIs
StatePublished - Apr 2012

Keywords

  • Angiogenesis
  • Esophageal
  • Gastroesophageal junction
  • Paclitaxel
  • Sunitinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Sunitinib plus paclitaxel in patients with advanced esophageal cancer: A phase II study from the Hoosier Oncology Groupe'. Together they form a unique fingerprint.

Cite this